Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial

Journal:

The Lancet Oncology

Published:

2025-11-26

DOI:

10.1016/s1470-2045(25)00545-5

Affiliations:

12

Authors:

20

Go to article

Institutions	Authors	Share
State Key Laboratory of Oncology in South China, SYSUCC, China	11.000000 11.000000	0.55
Guangdong Academy of Medical Sciences (Guangdong Provincial People’s Hospital), China	1.000000	0.05
Lianjiang People's Hospital, China	1.000000	0.05
Harbin Medical University Cancer Hospital, China	1.000000	0.05
Second Affiliated Hospital, SCUT, China	1.000000	0.05
Guangdong Provincial Hospital of Traditional Chinese Medicine, GZUCM, China	1.000000	0.05
The Second Affiliated Hospital, GMU, China	1.000000	0.05
Haikou Hospital, China	1.000000	0.05
The First Affiliated Hospital, SYSU, China	1.000000	0.05
Guangdong Women and Children Hospital, China	1.000000	0.05

Interested in Oncology and Carcinogenesis?